Could a targeted drug shrink advanced cervical tumors?
NCT ID NCT04205799
First seen Jun 29, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This phase 2 trial tests the drug cabozantinib in women with advanced or metastatic cervical cancer that has worsened after platinum-based chemotherapy. The study aims to see if cabozantinib can control the disease and how safe it is, particularly regarding risks like fistulas. Participants take a daily 60 mg pill in 4-week cycles until the cancer progresses or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cabozantinib
- What this could lead to
- If effective, cabozantinib could offer a new treatment option for advanced cervical cancer when standard chemotherapy stops working.
- What could go wrong
- This is a small, early-phase trial, so results may not confirm benefit. Cabozantinib can cause serious side effects like fistulas or perforations in the gut or urinary tract.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC CERVICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre François Baclesse
Caen, France
-
Centre Léon Bérard
Lyon, France
-
Centre Oscar LAMBRET
Lille, France
-
Institut CURIE
Saint-Cloud, France
-
Institut Gustave Roussy
Villejuif, France
-
Institut de Cancérologie de Montpellier
Montpellier, France
-
Institut de cancérologie de l'Ouest
Angers, France
-
Institut de cancérologie de l'Ouest
Nantes, France